After nearly a century building a company worth $125 billion based on injectable drugs, Denmark’s Novo Nordisk – the world’s biggest insulin maker – wants to prove this year it can transform the diabetes market with a pill.
Ook interessant voor je
After nearly a century building a company worth $125 billion based on injectable drugs, Denmark’s Novo Nordisk – the world’s biggest insulin maker – wants to prove this year it can transform the diabetes market with a pill.
Pharmamarketeer richt zich op marketingprofessionals van farmaceuten en andere medisch-gerelateerde organisaties in Nederland en België.
Copyright 2023 © Uitgave van MedHealth Communications BV | Privacy disclaimer
Reageer